Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(9):683; doi:10.1093/jnci/95.9.683
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Du, X. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, X. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 9, 683, May 7, 2003
© 2003 Oxford University Press

CORRESPONDENCE

Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975–1999

Xianglin L. Du

Correspondence to: Xianglin L. Du, M.D., Ph.D., Department of Internal Medicine, University of Texas Medical Branch, 3.134 Jennie Sealy Hospital, 301 University Blvd., Galveston, TX 77555–0460 (e-mail: xdu@utmb.edu).

The first 10% of the full text of this article appears below.

Mariotto et al. (1) presented unique information on trends in use of adjuvant chemotherapy and tamoxifen for breast cancer in the United States from 1975 through 1999, using data from eight registries of the SEER1 program. In their study, information on adjuvant chemotherapy from the Patterns of Care studies was also used to correct the SEER bias due to underreporting (1. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?